BioCentury
ARTICLE | Company News

Chiome, ADC Therapeutics deal

August 3, 2015 7:00 AM UTC

Chiome’s LivTech Inc. subsidiary granted ADC an option for exclusive, worldwide rights to develop LIV-1205 as an antibody-drug conjugate (ADC) to treat cancer. Upon exercise, LivTech will receive an ...